Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
Manman Deng(Xiamen University), Ken H. Young(Duke Medical Center), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Benjamin M. Parsons(Gundersen Health System), Maurilio Ponzoni(San Raffaele University of Rome), Feng Zhu(Xuzhou Medical College), Eric D. Hsi(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), April Chiu(Mayo Clinic), Bing Xu(Shandong University of Traditional Chinese Medicine), Hua You(Soochow University), Phillip Liu(Amgen (United States)), Youli Zu(Methodist Hospital), Wayne Tam(Cornell University), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Xiaosheng Fang(Shandong Provincial Hospital), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Jooryung Huh(Asan Medical Center), Xudong Wang(Zhejiang University of Technology), Yong Li(Baylor College of Medicine), Fredrick Hagemeister(The University of Texas MD Anderson Cancer Center), Jane N. Winter(Northwestern University), Lan V. Pham(Pharmacyclics (United States)), Michael Møller(Hospital South West Jutland)
Cited by 38
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Circular RNAs function as ceRNAs to regulate and control human cancer progression
|Molecular Cancer|2018|1.1k